- NeuroMetrix (NURO) applies for marketing clearance in China for its NC-stat DPNCheck peripheral neuropathy detection device. Once cleared, it will be marketed by the company's partner for Asian markets Omron Healthcare.
- Approximately 100M Chinese have diabetes which comprises almost one quarter of the world total, making it the largest peripheral neuropathy diagnostic market by volume.
NC-stat DPNCheck regulatory submission in China
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs